BioInvent Breaks Ground: Commences Subcutaneous Phase 1/2 Trial of BI-1206 for Solid Tumors

BioInvent Hits Milestone: Initiates Patient Treatment with Convenient Subcutaneous BI-1206 for Solid Tumors

LUND, SE / ACCESSWIRE / September 08, 2023 / In a groundbreaking development, BioInvent International AB (Nasdaq Stockholm: BINV), a pioneering biotech company dedicated to the innovative world of immune-modulatory antibodies for cancer immunotherapy, proudly announces the enrollment of the inaugural patient in its Phase 1/2 trial (NCT04219254; KEYNOTE-A04). This trial, conducted in partnership with MSD’s (Merck & Co., Inc., Rahway, NJ., USA) KEYTRUDA® (pembrolizumab), focuses on exploring the potential of a subcutaneous (SC) formulation of the trailblazing anti-FcyRIIB antibody BI-1206, designed to combat solid tumors.

The introduction of SC administration marks a significant leap forward in terms of patient convenience and treatment flexibility compared to traditional intravenous (IV) methods. The ongoing Phase 1/2 BI-1206 trial, administered alongside rituximab for non-Hodgkin’s lymphoma (NHL), has already demonstrated pharmacokinetically equivalent doses to IV, enhancing exposure and receptor engagement as anticipated. Importantly, no safety or tolerability concerns have arisen.

This trial targets advanced solid tumor patients who have experienced progression post-previous treatments, including PD-1/PD-L1 immune checkpoint inhibitors. Patients will undergo three-week cycles of BI-1206 paired with pembrolizumab, spanning up to two years or until disease progression. Early indications of efficacy have been reported from the IV segment of the study, with two partial responses and two stable disease cases among the 18 evaluable patients receiving BI-1206+pembrolizumab, as of June 7, 2023.

Martin Welschof, CEO of BioInvent, expressed his optimism, stating, “We are thrilled to advance BI-1206 through clinical development, offering the simplicity of subcutaneous administration. The promising results achieved in this heavily treated patient population further solidify our belief in BI-1206’s potential to transform the lives of patients grappling with non-Hodgkin lymphoma and solid tumors. Our commitment remains steadfast in enhancing cancer treatment and patient well-being.”

Notably, KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a dynamic biotech trailblazer, currently navigating the clinical stage with four groundbreaking drug candidates across five ongoing Phase 1/2 trials. These pioneering therapies are designed to revolutionize cancer treatment, targeting both hematological cancer and solid tumors.

Fueling our innovation is the proprietary F.I.R.S.T™ technology platform, a true game-changer in identifying therapeutic targets and the antibodies that lock onto them. This transformative platform not only powers our robust clinical pipeline but also presents lucrative licensing and partnering prospects.

Our revenue streams flow from research collaborations and licensing agreements with top-tier pharmaceutical giants, further enriched by our in-house antibody manufacturing capabilities. At BioInvent, we’re not just shaping the future of cancer therapy; we’re actively partnering with it.

Leave a Comment